Related Experiment Video
Updated: Nov 3, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Population (Antibody) Testing for COVID-19-Technical Challenges, Application and Relevance, an English Perspective
1Clinical Neurology Research Group, Department of Neurology, Division of Clinical Neuroscience, University of Nottingham School of Medicine, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Insights
Accurate population testing for SARS-CoV-2 immunity is crucial for monitoring COVID-19 spread and vaccine effectiveness. Challenges in developing sensitive antibody tests must be overcome to measure seroprevalence and herd immunity effectively.
Area of Science:
- Virology
- Immunology
- Epidemiology
Background:
- Population-based infection and immunity data are vital for disease surveillance and intervention assessment.
- Previous population testing in the UK covered diseases like measles, mumps, rubella, hepatitis, and HIV.
- Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) presents unique biological challenges for immunity testing.
Purpose of the Study:
- To discuss the challenges in SARS-CoV-2 infection testing, focusing on population-based immunity.
- To highlight the need for sensitive and specific antibody assays for seroprevalence and protection assessment.
- To address the urgent requirement for measuring vaccine efficacy and herd immunity development.
Main Methods:
- Review of existing population testing methodologies for infectious diseases.
- Analysis of biological properties of SARS-CoV-2 impacting immunity testing.
- Consideration of antibody assay development for sensitivity and specificity.
Main Results:
- Limited population virus or antibody testing has been performed for various diseases in the UK.
- Developing accurate SARS-CoV-2 immunity tests faces significant challenges.
- The availability of COVID-19 vaccines necessitates robust methods for efficacy and herd immunity measurement.
Conclusions:
- Effective population-based immunity testing for SARS-CoV-2 is essential for pandemic management.
- Overcoming technical hurdles in antibody assay development is critical.
- National studies are crucial for understanding SARS-CoV-2 infection and immunity within the UK population.
Abstract:
In the UK, population virus or antibody testing using virus swabs, serum samples, blood spots or oral fluids has been performed to a limited extent for several diseases including measles, mumps, rubella and hepatitis and HIV. The collection of population-based infection and immunity data is key to the monitoring of disease prevalence and assessing the effectiveness of interventions such as behavioural modifications and vaccination. In particular, the biological properties of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its interaction with the human host have presented several challenges towards the development of population-based immunity testing. Measuring SARS-CoV-2 immunity requires the development of antibody assays of acceptable sensitivity and specificity which are capable of accurately detecting seroprevalence and differentiating protection from non-protective responses. Now that anti-COVID-19 vaccines are becoming available there is a pressing need to measure vaccine efficacy and the development of herd immunity. The unprecedented impact of the SARS-CoV-2 pandemic in the UK in terms of morbidity, mortality, and economic and social disruption has mobilized a national scientific effort to learn more about this virus. In this article, the challenges of testing for SARS-CoV-2 infection, particularly in relation to population-based immunity testing, will be considered and examples given of relevant national level studies.
More Related Videos
08:21Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera
Published on: May 23, 2025
08:52Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019